Drug Trial Radar · NCT07913009
Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Hepatic Impairment
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 16, 2026
Primary completion
Dec 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to compare the pharmacokinetics, safety of HSK31858 in subjects with mild, moderate, severe hepatic impairment and normal hepatic function.
Conditions
- Non-cystic Fibrosis Bronchiectasis (NCFBE)
Interventions
HSK31858 tabletsDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Post-dose at day 1 to day 14.
- AUC0-tTime frame: Post-dose at day 1 to day 14.
- AUC0-∞Time frame: Post-dose at day 1 to day 14.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Infectious Disease Hospital (Zhengzhou No.6 People's Hospital)
Zhenzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.